Drug Trial Radar · NCT06747468
Avexitide for Treatment of Post-Bariatric Hypoglycemia
Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Apr 29, 2025
Primary completion
Jul 8, 2026
Study completion Feb 2027
Sponsor
- Lead sponsor
- Amylyx Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
AVX-001 (LUCIDITY) is a Phase 3 study to evaluate avexitide compared to placebo in participants with post bariatric hypoglycemia (PBH) related to Roux-en-Y gastric bypass (RYGB). The study will assess avexitide compared to placebo for safety and efficacy, measured by reduction of hypoglycemic events. The study includes a Screening period with a Run-in period (of up to 6- and 3-weeks, respectively); a randomized, double-blind, placebo-controlled study treatment period of 16 weeks; and a two-part open-label extension (OLE) period with a duration of approximately 32 weeks.
Conditions
- Post Bariatric Hypoglycemia
Interventions
AvexitideDrug
Avexitide (also known as exendin 9-39), a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, is a 31-amino acid peptide with a free amino group at the N-terminus and an amidated C-terminus. By binding to the GLP-1 receptor, avexitide inhibits GLP-1 receptor signaling, thereby reducing GLP-1 receptor-mediated insulin secretion
PlaceboOther
Matching placebo comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite rate of Level 2 and Level 3 hypoglycemic eventsTime frame: During the double-blind treatment period (approximately 16 weeks)
- Safety and Tolerability of avexitideTime frame: During the double-blind treatment period (approximately 16 weeks)
- Incidence of anti-drug antibodies (ADAb)Time frame: During the double-blind treatment period (approximately 16 weeks)
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
Stanford Health Care - Endocrinology Clinic
Stanford, California
University of Colorado Health Anschutz Medical Campus
Aurora, Colorado
East Coast Institute for Research
Jacksonville, Florida
Hanson Diabetes Center
Port Charlotte, Florida
Georgia Clincal Research
Lawrenceville, Georgia
Cotton-O'Neil Diabetes and Endocrinology Center
Topeka, Kansas
Brigham and Women's Hospital
Boston, Massachusetts
Joslin Diabetes Center
Boston, Massachusetts
NYC Health + Hospitals/Queens - BRANY
New Hyde Park, New York
Duke Center for Metabolic and Weight Loss Surgery
Durham, North Carolina
Centricity Research Morehead City Multispecialty
Morehead City, North Carolina
Cleveland Clinic
Cleveland, Ohio
Penn Medicine University City
Philadelphia, Pennsylvania
Vanderbilt Weight Loss Center
Nashville, Tennessee
Endocrine and Psychiatry Center
Houston, Texas
Southern Endocrinology & Diabetes Associates
Mesquite, Texas
UT Health San Antonio
San Antonio, Texas
Diabetes and Gandular Disease Clinic
San Antonio, Texas
Consano Clinical Research
Shavano Park, Texas
Texas Valley Clinical Research, LLC
Weslaco, Texas
UWHealth - Junction Rd Medical Center Endocrinology Clinic
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.